Achieving visual excellence through optimisation of macular pigment

Article

Enrichment of MP can enhance visual performance

The field of ophthalmology is concerned with the detection and treatment of eye disease, and alleviation or amelioration of the pathology's impact on vision. However, there is a fundamental and unmet need to recognize the considerable and underappreciated variability in visual performance and experience in healthy patients with no evidence of eye disease. In this context, visual performance, reflected in the subject's visual experience, can be assessed with a variety of techniques, and should not be restricted to standard and typical visual acuity (VA) testing.

Measures of visual performance

VA is a useful tool for testing the resolving power of the eye. It involves the presentation of a target that has a substantially different luminance to its background. The subject's task is to read the line of the smallest letters visible to him/her. However, VA's limitations rest primarily on the fact that testing is performed under conditions of 100% contrast, and therefore does not reflect the subject's function in relation to vision because so many other parameters of the visual experience are not being tested.

Contrast Sensitivity

Contrast sensitivity (CS) refers to the ability of the visual system to distinguish an object from its background.1 High contrast involves the presentation of two visual stimuli of substantially different luminance, whereas low contrast involves the presentation of two visual stimuli of comparable luminance. CS testing determines the lowest level of contrast required to detect the target against its background.

CS is adversely affected by increasing age, cataracts, diabetic maculopathy and age-related macular degeneration (AMD), even in cases where measures of VA are unaffected. Measures of CS have been shown to better represent the impact of eye disease on a subject's visual function than do measures of VA.2 This is unsurprising, given that the real world visual experience is not confined to a high contrast environment.

Importantly, and especially in the context of this review, CS is adversely affected by chromatic aberration (CA) to a greater extent than is VA.3

Glare

Glare refers to a reduction in visual performance or a sense of discomfort because of a relatively bright light source within the field of view.4 Clinically, there are two types of glare, and these can be classed as glare discomfort and glare disability. Glare discomfort refers to an unpleasant sensation one experiences when subjected to illumination that is too bright, for example, full beam headlights from an approaching vehicle when driving. Glare disability, however, refers to a reduction in one's ability to perceive visual information (without necessarily causing discomfort) because of a relatively bright light source in the field of vision.5 CS is adversely affected by glare disability, and this deleterious impact on CS is attributable to veiling luminance (which in turn is caused by light scattering), ultimately adversely impacting the visibility of objects in one's field of view.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Related Content
© 2025 MJH Life Sciences

All rights reserved.